The SAP18 agonist compound, A671, with potent inhibitory effect against T-cell lymphoma and erythroleukemia through SIRT3 downregulation needs further investigation for the treatment of these, and other malignancies in which the SAP18/SIRT3 regulatory axis is intact. This evidence concerns the gene SIRT3 and T-cell non-Hodgkin lymphoma.